GlassScriptPhysician profile
Henry A Perez
NPI 1477225365
$1,263.51
in general payments reported to CMS, 2019-2025
20 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $427 · 2024: $290 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $219.24 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.66 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $109.69 | 2022-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $108.92 | 2023-2024 | Austedo Xr, Austedo |
| Shield Therapeutics INC | $101.28 | 2024-2025 | |
| Abbvie INC. | $88.18 | 2023-2025 | |
| Exact Sciences Corporation | $84.52 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $64.98 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.42 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $54.60 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $46.62 | 2022-2025 | Wegovy |
| Amgen INC. | $31.74 | 2023-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $26.94 | 2025 | |
| Amarin Pharma, INC. | $20.06 | 2022 | |
| Glaxosmithkline, LLC. | $19.12 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.88 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $18.75 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $18.07 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2024 | Jardiance, Tradjenta |
| Hikma Pharmaceuticals USA | $15.47 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.